RxDoctor Payments Data

Brooke Cantu, APRN

Nurse Practitioner · Chicago, ILNPI 1659048015

Payments from drug & device makers

$971in general payments, 2019–2025

Across 22 payments — averaging $44.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$211
  • Abiomed$198
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$170
  • Novo Nordisk$121
  • Novartis$108
  • Boston Scientific$87
  • plus $76 from 2 others

What the payments were for

  • Food & beverage$971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$971 in reported general payments places this provider in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$42,385
Medicare patients
303
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin170$245,163
EliquisApixaban163$191,615
EntrestoSacubitril/Valsartan83$121,659
MounjaroTirzepatide73$87,186
Repatha SureclickEvolocumab78$78,365
XareltoRivaroxaban31$33,368
OzempicSemaglutide20$32,682
VascepaIcosapent Ethyl37$17,483
TrulicityDulaglutide14$15,790
Icosapent Ethyl20$7,123
Rosuvastatin Calcium225$3,584
Ranolazine ErRanolazine16$3,468
Ezetimibe163$3,216
Metoprolol Succinate219$2,849
Carvedilol219$2,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$108$121,65983 claims
Novo NordiskOzempic$121$32,68220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →